Form 4: Enliven Therapeutics Officer Helen Collins Reports Stock Option Exercise and Sale

Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics, exercised stock options and sold shares on October 18, 2024, according to a Form 4 filing.

Summary

• On October 18, 2024, Helen Louise Collins, the Chief Medical Officer of Enliven Therapeutics, exercised stock options to acquire 816 shares of common stock at a price of $2.48 per share.
• Simultaneously, Collins sold 816 shares of common stock at a weighted average price of $30.003 per share, with individual sales ranging from $30.00 to $30.03.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 19, 2023.
• Following these transactions, Collins directly owns 0 shares of common stock.
• Collins still holds options for 266,268 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports transactions by an officer. The use of a 10b5-1 plan suggests pre-planned and compliant activity.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates activity by a key executive at Enliven Therapeutics.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by a company officer.
• The impact is likely minimal given the relatively small number of shares involved and the pre-planned nature of the transactions.

Key Dates